Taro Pharmaceuticals (TARO)

Executive Summary

Taro Pharmaceuticals is a leading U.S. generic drug manufacturer specializing in topical dermatological products and solid oral dosage forms for cardiology and neurology. Founded in 1950 and headquartered in Hawthorne, New York, the company markets a broad portfolio of prescription and over-the-counter products. In recent years, Taro has focused on expanding its pipeline of complex generics and dermatology offerings, leveraging its manufacturing expertise to gain market share in niche therapeutic areas. As a private company under Sun Pharmaceutical Industries, Taro benefits from strong parent support and distribution networks. Despite generic pricing pressures, Taro's strategic emphasis on high-barrier-to-entry products positions it for steady growth. Upcoming catalysts include potential FDA approvals for novel generic formulations, launch of new dermatology products, and expansion in oral solid dosage forms. The company's strong balance sheet and manufacturing capabilities support its competitive advantage.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of generic Tacrolimus ointment (Protopec® generic)80% success
• Q2 2026Launch of generic Dextroamphetamine/amphetamine ER capsules (Adderall XR® generic)75% success
• TBDExpansion of topical creams pipeline with new ANDA submissions60% success